Christina Kay
2022
In 2022, Christina Kay earned a total compensation of $276.3K as Co, Chief Executive Officer at Integrated Biopharma, a 12% increase compared to previous year.
Compensation breakdown
| Option Awards | $39,151 |
|---|---|
| Salary | $228,398 |
| Other | $8,702 |
| Total | $276,251 |
Kay received $228.4K in salary, accounting for 83% of the total pay in 2022.
Kay also received $39.2K in option awards and $8.7K in other compensation.
Rankings
In 2022, Christina Kay's compensation ranked 5,108th out of 5,669 executives tracked by ExecPay. In other words, Kay earned more than 9.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,108 out of 5,669 | 10th |
Division Manufacturing | 2,807 out of 3,081 | 9th |
Major group Chemicals And Allied Products | 1,306 out of 1,396 | 6th |
Industry group Drugs | 1,227 out of 1,297 | 5th |
Industry Pharmaceutical Preparations | 889 out of 940 | 5th |
Source: SEC filing on October 27, 2022.
Kay's colleagues
We found four more compensation records of executives who worked with Christina Kay at Integrated Biopharma in 2022.
News
Integrated Biopharma CFO Dina Masi's 2024 pay rises 8% to $357K
October 28, 2024
Integrated Biopharma CFO Dina Masi's 2023 pay rises 10% to $330K
October 27, 2023
Integrated Biopharma CFO Dina Masi's 2022 pay rises 12% to $300K
October 27, 2022
Integrated Biopharma CFO Dina Masi's 2021 pay rises 6% to $268K
October 27, 2021
Integrated Biopharma CFO Dina Masi's 2019 pay rises 4% to $251K
October 28, 2019